BSECompany Update19h ago · 18 Nov 2026, 12:39 pm
Please find attached herewith Q2 H1FY2027 - Earnings Conference Call Transcript
Alkem Laboratories Ltd · 539523
✦ AI SummaryResults
Alkem Laboratories Ltd has released the transcript of its Q2 H1FY2027 Earnings Conference Call, hosted by Motilal Oswal Financial Services Limited. The call was recorded and the audio recording and transcript will be made available on the stock exchanges and the company's website shortly after the conclusion of the call. The company's financial results for the quarter and the first half of the year were announced earlier today, and the press release and investor presentation are filed with the stock exchanges and available on the company's website.
Analysis Scores
Earnings Impact8/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment7/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Attachments (1)
📄pdf
Download →
32c28174-e2ca-4146-a721-562e8df7fdc5.pdf
View document text
18th November, 2026
The Corporate Relationship Department National Stock Exchange of India Limited
BSE Limited Exchange Plaza,
Phiroze Jeejeebhoy Towers, Bandra Kurla Complex,
Dalal Street, Bandra East,
Mumbai 400 001. Mumbai 400 051.
Scrip Code: 539523 Scrip Symbol: ALKEM
Sub: Q2 & H1FY2027 - Earnings Conference Call Transcript
Dear Sir(s) / Madam,
We enclose herewith the transcript of “Q2 & H1FY2027 Earnings Conference Call” which was
hosted by the Company on Thursday, 12th November, 2026.
The said transcript shall also be made available on the website of the Company.
Kindly take the same on record.
Sincerely,
For Alkem Laboratories Limited
Manish Narang
President - Legal, Company Secretary & Compliance Officer
Encl.: a/a
“Alkem Laboratories Limited
Q2 FY27 Earnings Conference Call”
November 12, 2026
MANAGEMENT: MR. SANDEEP SINGH – MANAGING DIRECTOR –
ALKEM LABORATORIES LIMITED
DR. AMRUT NAIK – CHIEF EXECUTIVE OFFICER –
ALKEM LABORATORIES LIMITED
MR. DISHANT HITESH DOSHI – DEPUTY CHIEF
FINANCIAL OFFICER – ALKEM LABORATORIES
LIMITED
MR. SMEETT JAIN – HEAD OF INVESTOR RELATIONS –
ALKEM LABORATORIES LIMITED
MODERATOR: MR. TUSHAR MANUDHANE – MOTILAL OSWAL
FINANCIAL SERVICES LIMITED
Page 1 of 17
Alkem Laboratories Limited
November 12, 2026
Moderator: Ladies and gentlemen, good morning and welcome to the Alkem Labs Q2 FY27 Earnings
Conference Call hosted by Motilal Oswal Financial Services Limited. As a reminder, all
participant lines will be in the listen-only mode, and there will be an opportunity for you to ask
questions after the presentation concludes. Should you need assistance during the conference
call, please signal for an operator by pressing star then zero on your touch-tone phone. Please
note that this conference is being recorded.
I now hand the conference over to Mr. Tushar Manudhane. Thank you, and over to you, sir.
Tushar Manudhane: Thanks, Shaurya. Good evening, everyone, and a warm welcome to the second quarter of FY
2027 earnings call of Alkem Laboratories. From the management side, we have Mr. Sandeep
Singh, Managing Director, Dr. Amrut Naik, Chief Executive Officer, Mr. Dishant Hitesh Doshi,
Deputy CFO, and Mr. Smeett Jain, Head of Investor Relations. Over to you, Smeett.
Smeett Jain: Thank you, Tushar. Good evening, everyone. On behalf of Alkem Laboratories, I welcome you
to our Quarter two FY 2027 earnings call. Earlier today, we announced our financial results
along with the press release and investor presentation, all of which are filed with the stock
exchanges and are also available on our website. We hope you had an opportunity to review
them.
Before we begin, I would like to remind everyone that this call is being recorded, and the audio
recording and the transcript will be made available on the stock exchanges and our website
shortly after the conclusion of the call. Please also note that today's discussion may include
certain forward-looking statements, and these statements should be viewed in conjunction with
the risks and uncertainties that are associated with our business and the environment in which
we operate.
With that, I now would like to hand over the call to our MD, Mr. Sandeep Singh, for his insights.
Over to you, sir.
Sandeep Singh: Thank you, Smeett. Good evening, everyone.
Before I discuss the quarter's performance, I am pleased to welcome Dr. Amrut Naik, who has
joined Alkem Labs as Chief Executive Officer. Dr. Naik brings extensive industry experience
and will work closely with the leadership team to further strengthen execution and advance the
group's strategic priorities. On behalf of the Alkem board and entire Alkem team, I welcome
him and wish him great success in this new role. Before I go further, I would invite Amrut to
introduce himself to the investors and analysts over here. Thank you. Amrut, over to you.
Amrut Naik: Thank you, Sandeep. Good evening, all of you. Indeed a privilege and an honor to be here with
you, and happy to have you on the call this afternoon. My name is Amrut Naik. I've joined
Alkem as of yesterday as the CEO for the pharmaceutical business, and I come in with about 27
years of experience in the commercial area, leading businesses largely in overseas markets,
including the developed and the developing world. Happy to speak further as we move forward.
Thank you.
Sandeep Singh: Thank you, Amrut.
Page 2 of 17
Alkem Laboratories Limited
November 12, 2026
Coming to quarter two, we saw a healthy momentum across our India and international business.
Our India formulations business performed broadly in line with the market, supported by
continued strength in the chronic portfolio. The non-U.S. markets delivered steady underlying
performance, led by LATAM, while reported growth also benefited from the integration of
Occlutech.
In the U.S., volume growth provided support despite the prevailing pricing environment. We
also made progress across our newer growth platforms. During the quarter, we integrated
Occlutech into our MedTech business, with its financial performance consolidated into our
results from this quarter. In biotech, improving execution of operating performance at Enzene
remains a key priority.
As we move into the second half, our focus remains on sustaining growth in the core business
and strengthening execution across our operations, addressing regulatory priorities in Daman,
and developing our MedTech and biotech platforms in a disciplined manner.
I will briefly walk you through the key developments and outlook, after which we'll be happy to
take your questions and engage in discussions.
Our revenue from operations was INR4,520 crores, year-on-year growth of 13.8%. Biotech sales
was INR 70 crores with year-on-year degrowth of 35%, but that's due to the lumpy business
nature of the CDMO. MedTech sales were INR 133 crores. That includes Occlutech.
EBITDA was INR1,025 crores, resulted in a EBITDA margin of 22.5%, a growth of 11.3% year-
on-year. R&D expenses were 4.3% of our revenues. Profit before tax grew 7.7% year-on-year.
Net profit saw a degrowth of 11.7%, and net cash stood at INR4,900 crores plus.
According to IQVIA, we saw the company register a growth of 13.8% year-on-year, at par with
the Indian pharmaceutical industry, which grew at 13.8% as well. Acute segment reported a
growth of 12.1% at par with the IPM growth of 12.3%. Chronic segment reported a growth of
22.4% versus the industry, which grew by 16%, 640 basis points outperformance. We have
outperformed IPM in eight key focus therapies. In multivitamins by ~1.2x, anti-diabetic again
~1.5x, cardiac by 1.1x. Urology, again on a low base, we are 1.1x, Respiratory by 1.6x, Neuro
CNS by 1.1x & Derma by 1.6x.
On the regulatory front, remediation of our Daman facility is progressing, and we remain
engaged with the U.S. FDA to address the observation related to its OAI status. Separately, the
U.S. FDA inspection of our Mandva API facility concluded with no 483s. We are also committed
to maintaining the highest standards of quality and compliance across all our sites.
Thank you. With this, we open the floor for Q&A.
Moderator: Thank you very much. We will now begin with the question-and-answer session.
The first question is from the line of Saion Mukherjee from Nomura. Please go ahead.
Page 3 of 17
Alkem Laboratories Limited
November 12, 2026
Saion Mukherjee: On the India business, if you can highlight the dynamics that is leading to the slowdown in the
trade generics segment, and also on the prescription business, how you see growth shaping up
for the rest of the year and also for FY28?
Sandeep Singh: On trade generics, I think it is a question of just intensity going up of the market. I mean, I have
said this before, like few years back, there were much fewer players. Now you have all the
biggies jumping on the bandwagon as well. That is one. Number two, we have tightened our
own credit policies as well. So these kind of things have led to a growth, I mean, to a situation
where our growth is no longer the histor
[Showing first 8,000 characters — download PDF for full document]